IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jeff S. EDER

Application No. 10/717.026 Group Art Unit: 2121

Filed: November 19, 2003 Examiner: Michael Holmes

For: AN ENTITY CENTRIC COMPUTER SYSTEM

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendments Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO - 1449 and/or Substitute Form PTO - 1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior an should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Int	formation Disclosure Statement is being filed:					
	within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
X	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 3 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwis closes prosecution in the application, and includes one of:					
	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below)					
	O					
	the fee of \$180 set forth in 37 CFR 1, 1 7 (p) (see "Fees" below).					
	after the mailing date of a final action under 37 CFR 1. 113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(c) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 3 7 CFR 1. 17(p) (see "Fees" below).					
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.7(p) (see "Fees" below). NOTE,. This is for original applications except applications for a design patent filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.					
Copies	of the References					
	Copies of the references listed on the enclosed Form 1449 are enclosed herewith.					
X	This patent application was filed after June 30, 2003. Accordingly, copies of U.S. patents and patent applications that are listed on the accompanying Form 1449 are not enclosed herewith (see Official Gazette Notice of August 5, 2003). Copies of other references identified on the accompanying Form 1449 are enclosed herewith.					
	Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).					

the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s)	A copy of the foreign search report is enclosed herewith.
	Many of the references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

-	U.S. APPLI	CATIONS	Status (check one)				
	U.S. APPLICATIONS	U.S. Filing Date	PATENTED	PENDING	ABANDONED		
	1.						
	2.						
	3.						

Statement under 37 CFR 1.97(e)

	ıne	unaersign	iea nei	eby s	states	tnat	eacn	item	OT	ıntorn	nation	con	ainea	ın	tne
_	Infor	mation Dis	closure	State	ment v	was f	irst cite	ed in	any	comn	nunicat	tion f	rom a	fore	eign
	pate	nt office in	n a cou	nterpa	rt fore	ign p	atent	applic	ation	not	more '	than	three	mor	nths
	prior	to the filing	g of the	Inform	nation	Disclo	sure S	Staten	nent.						

The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Statement under 37 CFR 1.704(d)

The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement

Fees								
X	No fee is owed by the assignee(s).							
	The IDS Fee of \$180 under 37 CFR I. I 7(p) is enclosed herewith.							
inform	The Assignee respectfully requests consideration of the instant application with the ation disclosure statement attached herewith.							
Perpetially submitted								
Kespe	Respectfully submitted,							
/B.J. E	/B.J. Bennett/							

B.J. Bennett, President Asset Trust, Inc.

Date: September 11, 2007

PTO/SB/08A (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (As as many sheets as necessary)

of

Substitute for form 1449/PTO

US-

Sheet

				DOCUMENTS	
Examiner nitials*	Cite No.1	Document Number Number-Kind Code ² (F Annum)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 7,219,105 - B1	05-15-2007	Kummamuru et al.	All
		^{US-} 7.216.121 - B1	05-08-2007	Bachman et al.	All
		^{US-} 7.260,498 - B1	08-21-2007	Battenfelder et al.	All
		^{US-} 6.947,988 - B1	09-20-2005	Saleh, Nayal	All
		^{US-} 7,047,227 - B1	05-16-2006	Batachia et al.	All
		^{US-} 7,249,342 - B1	07-24-2007	Pack et al.	All
		^{US-} 7,162,379 - B1	01-09-2007	Jang et al	All
		^{US-} 7,170,510 - B1	01-30-2007	Kawahara et al.	All
		^{US-} 7,096,299 - B1	08-22-2006	Meynard, Olivier	All
		^{US-} 7,194,070 - B1	03-20-2007	Starbuck et al.	All
		^{US-} 7,246,080 - B1	7-17-2007	Feldman et al.	All
		^{US-} 6,317,787 - B1	11-13-2001	Boyd et al.	All
		US-			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages			
milao	110.	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	T Approximent of October 2000 and the	Or Relevant Figures Appear	T		
						L		
						L		
						Г		

Examiner	Date	
Signature	Considered	
. "		

"EXAMINES: Initial if reference considered, whether or not distino is in conformance with MPEP 609. Draw line through claim if not in conformance and not considered, include copy of this form with next communication to applicant." Applicant's unique catiation designation number (optionals) see (infact codes of USPTO Patient Documents at www.usplo.gov or MPEP 901.04. "3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patient footnowners, its middation of the year of the region of the Carpior must precede the serial number of the patient document and of communication of the year of the region of the Carpior must precede the serial number of the patient document and of the communication of the year of the region of the communication of the year of the region of the communication of the year of the region of the communication of the year of the region of

This collection of information is required by 3T CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is operand by 39 USC 122 and 3T CFR 114. This collection is estimated to lake 2 bours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this budgen, should be sent to the Chief Individual Case. Any comments and Trademark Office, P. Dos 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Sox 1450, Nexandris, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are		of information unless it contains a valid OMB control number.
Substitute for form 1449/PTO		Complete if Known
	Application Number	10/717,026
INFORMATION DISCLOSURE	Filing Date	11/19/2003
STATEMENT BY APPLICANT	First Named Inventor	Jeff S. Eder
(Use as many sheets as necessary)	Art Unit	2121
lose as many sheets as necessary	Examiner Name	Michael Holmes
Sheet of	Attorney Docket Number	AR - 57

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²					
		UNIVERSITY OF MARYLAND UNIVERSITY COLLEGE, "Intelligent Agents and how they are changing our learning", UMUC website, August 20, 2003						
-		ROLL, RICHARD, "A Mean/Variance Analysis of Tracking Error", pages 13 - 22, V18, Summer 1992, Journal of Portfolio Management, U.S.A.						
		GREEN, PAUL & KRIEGER, ANNA; "Models and Heuristics for Product Line Selection", Marketing Science, Volume 4, Number 1, pages 1 - 19, Winter 1995, U.S.A.						
		THE ENCODE PROJECT CONSORTIUM, "Identification and analysis of functional elements in 1% of the human genome", Nature, June 14, 2007, V 445, p 799 - 816, USA						
		HOCHMAN, JONATHAN, "Search Marketing and Web Page Download Speed", September 5, 2007, searchengineland.com						
		HYPKNOWSYS, "Web-Log Preparaton with WUM Prep", October 18, 2005, www.sourceforge.com						
		CARUSO, DENISE, "A challenge to gene theory, a tougher look at biotech", New York Times, July 1, 2007, New York, U.S.A.						

*EYAMINED: I	Will if of come and ideal of the beautiful in its confirmation in the MDED 60	Draw line through a	itation if not in conformance and not
Signature		Considered	

considered. Include copy of this form with next communication to applicant.

Evaminar

Consideration, include copy of the storm warm section and to deplete and the section of the sect gamening, preparing, and administration to complete dispination for the Corp. The variety experiency upon the inclination case. Any commission to the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S., Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.